CRISPR & Gene Editing News

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial CNBCIntellia races in vivo CRISPR therapy to FDA after phase 3 win Fierce BiotechIntellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial statnews.comIntellia is seeking FDA approval for what could be the first in vivo CRISPR gene editing therapy qz.comIntellia CRISPR drug succeeds in late-stage study against rare swelling disorder BioPharma DiveQ&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next Endpoints NewsNTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy Stocktwits